Lipoic acid in animal models and clinical use in diabetic retinopathy

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 13, 2013, Pages 1829-1838

  Nebbioso, Marcella ^a   Pranno, Federica ^a   Pescosolido, Nicola ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alpha lipoic acid; Antioxidant; Diabetes mellitus; Diabetic retinopathy; Oxidative stress; Reactive oxygen species

Indexed keywords

ANGIOPOIETIN 2; ERYTHROPOIETIN; SUPEROXIDE; THIOCTIC ACID; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; INSULIN SENSITIVITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERICYTE;

EID: 84881654000     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.813483     Document Type: Article

References (54)

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53
2. World Health Organization. The prevention of diabetes and its complications. WHO report. 2006.Available from: http:/www.who.int/diabetes/ preventionflyer/en/[Accessed on 7 August 2010]
3. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35(S1):64-71
5. Tavakoli M, Malik RA. Management of painful diabetic neuropathy. Expert Opin Pharmacother 2008;9:2969-78
6. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp Diabetes Res 2007;2007:43603
7. Goh SY, Cooper ME. The role of advanced glycation endproducts in progression and complications of diabetes. J Clin Endocrinol Metab 2008;93:1143-52
8. Machlin L, Bendich A. Free radical tissue damage: protective role of antioxidant nutrients. FASEB J 1987;1:441-5
9. Nebbioso M, Federici M, Rusciano D, et al. Oxidative stress in preretinopathic diabetes subjects and antioxidants. Diabetes Technol Ther 2012;14:257-63
10. Lopes de Jesus CC, Atallah AN, Valente O, Moça Trevisani VF. Vitamin C and superoxide dismutase (SOD) for diabetic retinopathy. Cochrane Database Syst Rev 2008;1):CD006695
11. Toshihiko O, Yoji K. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. Ann NY Acad Sci 2006;1043:440-51
12. Packer L, Witt E, Tritschler H. Alpha-lipoic as a biological antioxidant. Free Radic Biol Med 1995;19:227-50
13. Chidlow G, Schmidt K.-G, Wood J, et al. Alpha-lipoic acid protects the retina against ischaemic-reperfusion. Neuropharmacology 2002;43:1015-25
14. Bartlett HE, Eperjesi F. Nutritional supplementation for type 2 diabetes: a systematic review. Ophthal Physiol 2008;28:503-23
15. Nebbioso M, Scarsella G, Tafani M, Pescosolido N. Mechanisms of ocular neuroprotection by antioxidant molecules in animal models. J Biol Regul Homeost Agents 2013;27:197-209
16. Biewenga G, Haenen G, Bast A. The pharmacology of the antioxidant alpha-lipoic acid. Gen Pharmacol 1997;29:315-31
17. Johnsen-Soriano S, Garcia-Pous M, Arnal E, et al. Early lipoic acid intake protects retina of diabetic mice. Free Radic Res 2008;42:613-317
18. Borenshtein D, Ofri R, Werman M, et al. Cataract development in diabetic sand rats treated with alpha-lipoic acid and its gamma-linolenic acid conjugate. Diabetes Metab Res Rev 2001;17:44-50
19. Jacob S, Ruus P, Hermann R, et al. Oral adminstration of RAC-alpha-lipic acid modulates insulin senstivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med 1999;27:309-14
20. Santos JM, Kowluru RA. Role of mitochondria biogenesis in the metabolic memory associated with the continued progression of diabetic retinopathy and its regulation by lipoic acid. Invest Ophthalmol Vis Sci 2011;52:8791-8
21. Salvadó L, Serrano-Marco L, Barroso E, et al. Targeting PPARb/d for the treatment of type 2 diabetes mellitus. Expert Opin Ther Targets 2012;16:209-23
22. Dene BA, Maritim AC, Sanders RA, Watkins JB. Effects of antioxidant treatment on normal and diabetic rat retinal enzyme activities. J Ocul Pharmacol Ther 2005;21:28-35
23. Roberts R, Luan H, Berkowitz BA. Lipoic acid corrects late-phase supernormal retinal oxygenation response in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci 2006;47:4077-82
24. Jacob S, Rett K, Henriksen EJ, Häring HU. Thiotic acid-effects on insulin sensitivity and glucose-metaboliism. BioFactors 1999;10:169-74
25. Abiko T, Abiko A, Clermont AC, et al. Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes 2003;52:829-37
26. Berkowitz BA, Roberts R, Stemmler A, et al. Impaired apparent ion demand in experimental diabetic retinopathy: correction by lipoic acid. Invest Ophthalmol Vis Sci 2007;48:4753-8
27. Kowluru RA, Odenbach S, Effect of long-term administration of lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 2004;53:3233-8
28. Kowluru RA, Atasi L, Ho YS. Role of mitochondrial superoxide dismutase in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 2006;47:1594-9
29. Kowluru RA. Diabetic retinopathy: mitochondrial dysfunction and retinal capillary cell death. Antioxid Redox Signal 2005;7:1581-7
30. Kowluru RA. Effect of advanced glycation end products on accelerated apoptosis of retinal capillary cells under in vitro conditions. Life Sci 2005;76:1051-60
31. Artwohl M, Muth K, Kosulin K, et al. R-(+)-alpha-lipoic acid inhibits endothelial cell apoptosis and proliferation: involvement of Akt and retinoblastoma protein/E2F-1. Am J Physiol Endocrinol Metab 2007;293:681-9
32. Lin J, Bierhaus A, Bugert P, et al. Effect of R-(+)-a-lipoic acid on experimental diabetic retinopathy. Diabetologia 2006;49:1089-96
33. Lee SG, Lee CG, Yun IH, et al. Effect of lipoic acid on expression of angiogenic factors in diabetic rat retina. Clin Experiment Ophthalmol 2012;40:47-57
34. Obrosova IG, Minchenko AG, Marinescu V, et al. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 2001;44:1102-10
35. Obrosova IG, Stevens MJ, Lang HJ. Diabetes-induced changes in retinal NAD-redox status: pharmacological modulation and implications for pathogenesis of diabetic retinopathy. Pharmacology 2001;62:172-80
36. Wu H, Xu G, Liao Y, et al. Supplementation with antioxidants attenuates transient worsening of retinopathy in diabetes caused by acute intensive insulin therapy. Graefes Arch Clin Exp Ophthalmol 2012;250:1453-8
37. Kola B, Boscaro M, Rutter GA, et al. Expanding role of AMPK in endocrinology. Trends Endocrinol Metab 2006;17:205-15
38. Phipps JA, Fletcher EA, Vingrys AJ. Paired-flash identification of rod and cone dysfunction in the diabetic rat. Invest Ophthalmol Vis Sci 2004;45:4592-600
39. Hancock HA, Kraft TW. Oscillatory potential analysis and ERGs of normal and diabetic rats. Invest Ophthalmol Vis Sci 2004;45:1002-8
40. Kowluru RA, Odenbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 2004;53:3233-8
41. Haritoglou C, Gerss J, Hammes HP, et al. Alpha-lipoic acid for the prevention of diabetic macular edema. Ophthalmologica 2011;226:127-37
42. Stitt A, Gardiner TA, Alderson NL, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002;51:2826-32
43. Golbidi S, Badran M, Laher I. Diabetes and alpha lipoic acid. Front Pharmacol 2011;2(69):1-15
44. Ametov A, Barinov A, O'Brien P, et al. The Sensory Symptoms of Diabetic Polyneuropathy are improved witha-lipoic acid: The Sydney Trial. Diabetes Care 2003;3:770-6
45. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with a-lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Diabetes Care 2006;29:2365-70
46. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant a-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995;38:1425-33
47. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol 2004;3:173-89
48. Bresciani E, Bussi A, Bazzigaluppi E, Balestrieri G. Insulin autoimmune syndrome induced by a-lipoic acid in a caucasian woman: case report. Diabetes Care 2011;34(9):e146
49. Lupsa BC, Chong AY, Cochran EK, et al. Autoimmune forms of hypoglycemia. Medicine (Baltimore) 2009;88:141-53
50. Ishida Y, Ohara T, Okuno Y, et al. a-Lipoic acid and insulin autoimmune syndrome. Diabetes Care 2007;30:2240-1
51. Uchigata Y, Hirata Y, Omori Y, et al. Worldwide differences in the incidence of insulin autoimmune syndrome (Hirata disease) with respect to the evolution of HLA-DR4 alleles. Hum Immunol 2000;61:154-7
52. Al-Rasheed NM, Al-Rasheed NM, Attia HA, et al. Adverse cardiac responses to alpha-lipoic acid in a rat-diabetic model: possible mechanisms J Physiol Biochem 2013; Epub ahead of print
53. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alipoic acid). A two-year multicenter randomized double blind placebo controlled trial (ALADIN II). Free Rad Res 1999;31:171-9
54. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant a-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care 1997;20:369-73